Sangamo Therapeutics (NASDAQ:SGMO) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight progress across its Fabry disease and neurology pipelines, while repeatedly emphasizing that additional funding and a potential commercial partner remain central to the company’s ability to execute its plans. Fabry gene therapy advances with rolling BLA submission Chief Executive Officer […]

BioLineRx (NASDAQ:BLRX) executives highlighted progress on the company’s newly added oncology program GLIX1, provided updates on partnered motixafortide development efforts, and reviewed full-year 2025 financial results during its fourth-quarter and full-year conference call. GLIX1 set to enter first-in-human glioblastoma study CEO Phil Serlin said BioLineRx is preparing to initiate a first-in-human phase I/II-A clinical trial […]

Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting durable Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), plans to begin a Phase 3 registrational program in mid-2026, and upcoming clinical work for sepranolone. NDV-01 […]

Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a “major inflection point” for the company after favorable readouts from the CORAL trial […]

Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 million PIPE financing led by Point72. PIPE financing, warrant trigger, and cash runway Management said […]